97115 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus; Retroviridae, e.g. leukemia viruses Lentiviridae, e.g. HIV, FIV, SIV
Sub-classes:Anti-HIV Antibody 10-1074 Variants
#2ANTI-HIV VACCINE ANTIBODIES WITH REDUCED POLYREACTIVITY
#3RNA COMPOSITIONS TARGETING HIV
#4MULTISPECIFIC ANTIBODIES TARGETING MULTIPLE EPITOPES ON THE HIV-1 ENVELOPE
#5IMPROVED DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#6POLYPEPTIDE VARIANTS AND USES THEREOF
#7METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
#8BROADLY NEUTRALIZING ANTIBODIES THAT TARGET HIV ENV V3 N-GLYCANS
#9GENETICALLY ENGINEERED B CELLS AND METHODS OF USE THEREOF
#10CMV-HIV SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELLS
#11PLATFORM TECHNOLOGY FOR BISPECIFIC ANTIGENBINDING PROTEINS
#12METHODS AND SYSTEMS FOR APPLICATIONS INVOLVING ANTIGEN-PRESENTING CELLS
#13Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
#14NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO
#15DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10
#16HIV VACCINES AND METHODS OF USING
#17METHODS FOR OBTAINING ANTIBODY MOLECULES BINDING TO A PEPTIDE-MHC INTERFACE
#18Method of Redirecting T Cells to Treat HIV Infection
#19ANTIBODIES TARGETING HIV ESCAPE MUTANTS
#20HIV VACCINES AND METHODS OF USING
#21NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO
#22BISPECIFIC IMMUNE CELL ENGAGERS TARGETING HIV AND METHODS OF USE THEREOF
#23OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATE
#24DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#25GENE SEQUENCE CONSTRUCT FOR GENE THERAPY FOR HIV INFECTION
#26Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#27ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES TO TREAT HIV
#28BROADLY NEUTRALIZING ANTI-HIV-1 ANTIBODIES AND METHODS OF USE THEREOF
#29Human Immunodeficiency Virus Neutralizing Antibodies And Methods Of Use Thereof
#30ANTIBODIES, FRAGMENTS OR DERIVATIVES SPECIFICALLY BINDING TO A PROTEIN ANTIGEN CAPABLE OF BINDING TO NUCLEIC ACIDS AND USES OF SAME
#31SIALYDASE LINKED HIV ANTIBODIES AND METHODS OF USE
#32METHODS OF TREATING HIV-1 INFECTION UTILIZING BROADLY NEUTRALIZING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) GP120-SPECIFIC MONOCLONAL ANTIBODIES
#33DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV
#34BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV
#35HIV VACCINES AND METHODS OF MAKING AND USING
#36Dual cytokine fusion proteins comprising IL-10
#37Dual cytokine fusion proteins comprising IL-10
#38Dual cytokine fusion proteins comprising IL-10
#39Dual cytokine fusion proteins comprising IL-10
#40Dual cytokine fusion proteins comprising IL-10
#41Dual cytokine fusion proteins comprising IL-10
#42Dual cytokine fusion proteins comprising IL-10
#43Dual cytokine fusion proteins comprising IL-10
#44Dual cytokine fusion proteins comprising IL-10
#45Dual cytokine fusion proteins comprising IL-10
#46ENGINEERED CELLS AND USES THEREOF
#47T CELL RECEPTORS AND USES THEREOF
#48Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#49IMPROVED DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#50HIV-1 SPECIFIC ANTIBODIES AND USES THEREOF
#51Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#52UNIVERSAL CAR-NK CELL TARGETING VARIOUS EPITOPES OF HIV-1 GP160
#53RNA ENCODING AN ANTIBODY
#54DUAL CYTOKINE FUSION PROTEINS COMPRISING MULTI-SUBUNIT CYTOKINES
#55Broadly-Neutralizing HIV Antibodies
#56SYSTEMS AND METHODS TO PRODUCE B CELLS GENETICALLY MODIFIED TO EXPRESS SELECTED ANTIBODIES
#57HIV VACCINE COMPOSITIONS, METHODS, AND USES THEREOF
#58POTENT NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2, GENERATION AND USES THEREOF
#59ENGINEERED ANTIBODIES TO HIV ENV
#60CROSS-REACTIVE ANTIBODIES AND USES THEREOF
#61METHODS FOR MAKING EXTRACELLULAR VESICLES AND USES THEREOF
#62CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY
#63B cell receptor modification in B cells
#64NOVEL METHODS OF GENERATING ANTIBODIES
#65Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
#66GENE TRANSFER SYSTEM
#67BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV
#68Dual cytokine fusion proteins comprising IL-10
#69Dual cytokine fusion proteins comprising IL-10
#70Optimized crosslinkers for trapping a target on a substrate
#71GENOME ENGINEERING THE HUMAN IMMUNOGLOBULIN LOCUS TO EXPRESS RECOMBINANT BINDING DOMAIN MOLECULES
#72NK ENGAGER COMPOUNDS THAT BIND VIRAL ANTIGENS AND METHODS OF USE
#73Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
#74Dual cytokine fusion proteins comprising IL-10
#75ANTI-HIV VACCINE ANTIBODIES WITH REDUCED POLYREACTIVITY
#76Dual cytokine fusion proteins comprising IL-10
#77Dual cytokine fusion proteins comprising IL-10
#78Dual cytokine fusion proteins comprising IL-10
#79Dual cytokine fusion proteins comprising IL-10
#80IMMUNE CELL RECEPTORS COMPRISING CD4 BINDING MOIETIES
#81PLANT SERINE PROTEASES
#82Multispecific Anti-HIV Antibodies
#83HIV vaccines and methods of using
#84DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#85DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#86HIV/HCV CROSS-REACTIVE ANTIBODIES AND USES THEREOF
#87HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants
#88ANTIVIRAL IMMUNOTHERAPY BY MEMBRANE RECEPTOR LIGATION
#89Anti-HIV Antibody 10-1074 Variants
#90USE OF MODIFIED HIV-1 FOR GENERATING FULLY HUMAN ANTIBODIES
#91HIV-1 neutralizing antibodies and uses thereof
#92CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME
#93mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
#94ANTIBODY THERAPIES FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV)
#95Dual cytokine fusion proteins comprising IL-10
#96Broadly-neutralizing anti-HIV antibodies
#97ANTI-HIV ANTIBODY AND METHOD FOR PRODUCING SAME
#98THERAPEUTIC COMPOUNDS AND METHODS
#99METHOD FOR ENGINEERING IMMUNOGLOBULINS
#100METHODS FOR NONINVASIVE DETECTION, DIAGNOSIS AND TREATMENT OF DISEASE
#101HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE
#102Genome editing without nucleases
#103GENETIC ENGNEERING OF B CELL RECEPTORS AND USES THEREOF IN ANTIGEN-INDUCED ANTIBODY SECRETION
#104Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#105Antibody therapies for human immunodeficiency virus (HIV)
#106Systems and methods to produce B cells genetically modified to express selected antibodies
#107Multimeric IL-15-based molecules
#108DNA antibody constructs for use against HIV
#109Engineering pH-dependent antigen binding activity into anti-HIV antibodies with improved pharmacokinetics
#110Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#111ANTI-HIV ANTIBODIES
#112ANTI-HIV ANTIBODIES
#113ANTIBODY GENE EDITING IN B LYMPHOCYTES
#114OPTIMIZED CROSSLINKERS FOR TRAPPING A TARGET ON A SUBSTRATE
#115Genome Editing without Nucleases
#116MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE
#117HIV vaccines and methods of making and using
#118CD19-based chimeric antigen receptor and application thereof
#119HIV-1 SPECIFIC IMMUNOGEN COMPOSITIONS AND METHODS OF USE
#120ASSAY METHODS FOR IMPROVED ANALYTE DETECTION
#121Method of redirecting t cells to treat HIV infection
#122BINDING MOLECULES TARGETING PATHOGENS
#123Artificial secretion peptides for heterologous protein production
#124Multimeric IL-15-based molecules
#125Broadly neutralizing antibodies against HIV
#126Broadly neutralizing anti-HIV-1 antibodies and methods of use thereof
#127Polypeptide variants and uses thereof
#128Therapeutic compounds and methods
#129Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies in subjects with low viral loads
#130THERAPEUTIC COMPOUNDS AND METHODS
#131Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same
#132Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
#133RNA encoding an antibody
#134Compositions containing anti-HIV ostrich antibodies
#135Broadly-neutralizing anti-HIV antibodies
#136Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#137Single domain antibodies directed against arachidonate 12-lipoxygenase
#138Non-integrating viral delivery system and methods related thereto
#139NON-INTEGRATING VIRAL DELIVERY SYSTEM AND METHODS RELATED THERETO
#140Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#141Antiviral immunotherapy by membrane receptor ligation
#142Generation of human anti-HIV-1 ENV monoclonal antibodies with neutralizing activity from humanized mice infected with HIV-1
#143Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#144Methods for selectively expanding and enriching cells transduced with chimeric antigen receptors and treating HIV infection
#145DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#146DUAL SPECIFICITY POLYPEPTIDE MOLECULE
#147Dual specificity polypeptide molecule
#148Antibody and antibody-containing composition
#149COMPOSITIONS AND METHODS FOR REGULATABLE ANTIBODY EXPRESSION
#150IMMUNOASSEMBLIN (IA) PROTEIN COMPLEXES
#151Engineering Antiviral T Cell Immunity through Stem Cells and Chimeric Antigen Receptors
#152B cell lineage based immunogen design with humanized animals
#153High-throughput mouse model for optimizing antibody affinities
#154Broadly neutralizing antibody directed against HIV-1 GP140
#155Therapeutic compounds and methods
#156Expression of HIV inhibitors by mesenchymal stem cells
#157Method of redirecting T cells to treat HIV infection
#158Optimized crosslinkers for trapping a target on a substrate
#159HIV-1 neutralizing antibodies and uses thereof
#160Methods of generating antibodies
#161SUBCUTANEOUS RESERVOIR DEVICE AND METHOD OF MANUFACTURE
#162HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants
#163Cross-reactive T cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats
#164BINDING MOLECULES TARGETING PATHOGENS
#165Therapeutic composition of camel milk
#166HIV-1 neutralizing antibodies and uses thereof (CD4bs antibodies)
#167Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#168Antibody and antibody-containing composition
#169Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
#170Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides
#171ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE
#172Neutralizing GP41 antibodies and their use
#173METHOD FOR ENGINEERING IMMUNOGLOBULINS
#174Methods for modular synthesis of N-glycans and arrays thereof
#175Cell identification method
#176Antibodies With Simultaneous Subsite Specificities To Protein and Lipid Epitopes
#177Direct Method for providing Immunological Memory against HIV
#178Soluble engineered monomeric Fc
#179Single domain antibodies directed against human immunodeficiency virus
#180Single domain antibodies directed against ebola virus VP24
#181Genome editing without nucleases
#182Engineered antibody constant domain molecules
#183High-throughput mouse model for optimizing antibody affinities
#184Antibody and antibody-containing composition
#185Neutralizing GP41 antibodies and their use
#186HUMAN MONOCLONAL ANTIBODIES
#187Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
#188Anti-HIV domain antibodies and method of making and using same
#189Engineering antiviral T cell immunity through stem cells and chimeric antigen receptors
#190ANTIBODIES WITH ULTRALONG COMPLEMENTARITY DETERMINING REGIONS
#191THE USE OF ANTIBODIES IN TREATING HIV INFECTION AND SUPPRESSING HIV TRANSMISSION
#192METHOD FOR ENGINEERING IMMUNOGLOBULINS
#193Methods for producing antibodies
#194Broadly neutralizing antibody and uses thereof
#195METHODS AND KITS FOR THE DETECTION OF VIRAL INFECTIONS
#196Broadly-neutralizing anti-HIV antibodies
#197Antibodies with simultaneous subsite specificities to protein and lipid epitopes
#198Cross-reactive T cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats
#199Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#200BINDING MOLECULES TARGETING PATHOGENS
#201BROADLY NEUTRALIZING VHH AGAINST HIV-1
#202HIV antigens and antibodies and compositions, uses and methods thereof
#203Monomeric Forms of Human Aminoacyl-tRNA Synthetases Having Non-Canonical Biological Activities
#204Soluble engineered monomeric Fc
#205Delivery of proteins using adeno-associated virus (AAV) vectors
#206Neutralizing GP41 antibodies and their use
#207Neutralizing GP41 antibodies and their use
#208Human immunodeficiency virus neutralizing antibodies and methods of use thereof
#209Polypeptides having antiviral activity and methods for use thereof
#210ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION
#211Monoclonal antibodies directed against a novel pathogenic west African human immunodeficiency virus type 2 (HIV-2) group F isolate
#212B cell lineage based immunogen design with humanized animals
#213Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
#214Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody
#215METHODS FOR GENERATION OF ANTIBODIES
#216Engineered antibody constant domain molecules
#217Antibodies targeting HIV escape mutants
#218Single-domain antibodies that bind to HIV-1 Nef with high affinity
#219Adjuvant
#220Activatable toxin complexes comprising a cleavable inhibitory peptide
#221A NOVEL CHIMERIC PROTEIN FOR PREVENTION AND TREATMENT OF HIV INFECTION
#222Detection of feline immunodeficiency virus
#223Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
#224Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities
#225METHOD FOR THE GENERATION OF MONOCLONAL ANTIBODIES DERIVED FROM HUMAN B CELLS
#226METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION
#227Use of goat serum for veterinary treatment
#228Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
#229Delivery of proteins using adeno-associated virus (AAV) vectors
#230Treatment of Infection Using Single Chain Antibody Gene Therapy
#231Therapeutic using a bispecific antibody
#232Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region
#233Pathogenic west african human immunodeficiency virus type 2 (HIV-2) group F isolate
#234MOUSE MODELS
#235Therapeutic Agent
#236CHIMERIC RECEPTOR GENES AND CELLS TRANSFORMED THEREWITH
#237METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS
#238Use a goat serum for veterinary treatment
#239METHOD OF MAKING A VACCINE
#240NOVEL HUMAN ANTI-R7V ANTIBODIES AND USES THEREOF
#241Anti-HIV domain antibodies and method of making and using same
#242Monoclonal antibodies that bind to the V3 loop of HIV-1 gp120
#243Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
#244Dual Variable Domain Immunoglobulins and Uses Thereof
#245Engineered antibody constant domain molecules
#246Method for the detection of human immunodeficiency virus envelope (HIV) glycoprotein utilizing carbohydrate binding module (CBM) 20 or 21
#247CARBOHYDRATE BINDING MODULE AND USE THEREOF
#248Therapeutic Agent
#249Methods for generation of antibodies
#250Test method on feline vaccinated with feline immunodeficiency virus vaccine, and antigen for use in the test
#251REAGENT FOR DETECTING HIV-1 ANTIGEN AND DETECTION METHOD
#252In vitro human B lymphopoiesis culture system
#253Broadly Representative Antigen Sequences and Method for Selection
#254Polypeptide Recognized by Anti HIV-1 GP41 Antibodies Isolated from Highly HIV-1 Exposed, Non Infected Women
#255Method for engineering immunoglobulins
#256COMPOSITIONS AND METHODS FOR THE ANALYSIS AND TREATMENT OF AIDS WASTING SYNDROME AND IMMUNE CELL DYSFUNCTION
#257Multi-subtype FIV vaccines
#258Use of goat serum for veterinary treatment
#259Methods for detecting enveloped virus infections by measuring cell surface TSG101
#260Multivalent Immunogen
#261Anti-TSG101 antibodies and their uses for treatment of viral infections
#262Multi-subtype FIV vaccines
#263Method of inducing neutralizing antibodies to human immunodeficiency virus
#264Method of Treating Diseases and Disorders
#265Use of Goat Serum for Veterinary Treatment
#266Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
#267Chimeric protein for prevention and treatment of HIV infection
#268Therapeutic using a bispecific antibody
#269Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes
#270Lupus antibodies for passive immunotherapy of HIV/AIDS
#271Antibodies with simultaneous subsite specificities to protein and lipid epitopes
#272Method and device for detecting feline immunodeficiency virus
#273HIV TEV compositions and methods of use
#274PenetraBodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
#275Antigenic HIV gp41 chimeric polypeptides comprising the MVP5180/91 epitope SKGKLIS
#276Methods and compositions for impairing multiplication of HIV-1